Showing results (111-120 of 273) with videos related to
Sort By:
Pageof 28
Proceedings of the National Academy of Sciences of the United States of America|October 27, 2004
A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunctionStefano Fiorucci, John L Wallace, Andrea Mencarelli, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 28, 2020
The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagyAdriana Carino, Silvia Marchianò, Michele Biagioli, et al.Frontiers in Oncology|July 18, 2022
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor PrognosisCristina Di Giorgio, Silvia Marchianò, Elisabetta Marino, et al.Nutrients|May 24, 2019
Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets FormationAdriana Carino, Silvia Marchianò, Michele Biagioli, et al.Inflammation & Allergy Drug Targets|April 15, 2006
Nitric oxide and inflammationGiuseppe Cirino, Eleonora Distrutti, John L WallaceScientific Reports|January 28, 2023
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASHSilvia Marchianò, Michele Biagioli, Elva Morretta, et al.Liver Research|February 17, 2025
Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver diseaseMichele Biagioli, Stefano FiorucciCurrent Opinion in Pharmacology|June 17, 2006
PPARs and other nuclear receptors in inflammationGiovanni Rizzo, Stefano FiorucciJournal of Cellular and Molecular Medicine|January 1, 2010
FXR an emerging therapeutic target for the treatment of atherosclerosisAndrea Mencarelli, Stefano FiorucciExpert Opinion on Investigational Drugs|August 9, 2025
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectivesStefano Fiorucci, Ginevra UrbaniPageof 28